Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
89Bio Inc
(NQ:
ETNB
)
9.240
-0.420 (-4.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 89Bio Inc
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
March 22, 2023
Via
Benzinga
Why 89bio Shares Are Trading Higher Today
March 22, 2023
89bio (NASDAQ: ETNB) shares are trading higher on Wednesday after the company's Phase 2b ENLIVEN trial of pegozafermin in NASH achieved statistical significance on both primary histology endpoints.
Via
Benzinga
Nasdaq Edges Higher; Crude Oil Rises 1%
March 22, 2023
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite moving higher on Wednesday. The Dow traded down 0.15% to 32,512.83 while the NASDAQ rose 0.13% to 11,875.36. The S&P 500, also...
Via
Benzinga
89Bio Inc. (NASDAQ: ETNB) Near the Top of Equities by Percentage Gain on 3/22
March 22, 2023
Via
Investor Brand Network
89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)
March 22, 2023
89bio, Inc. (NASDAQ: ETNB) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of
Via
Spotlight Growth
Exposures
Product Safety
Analyst Ratings for 89bio
March 14, 2023
Via
Benzinga
Why Are Meme Stocks GME, AMC, BBBY Up Today?
March 22, 2023
Meme stocks are on the move Wednesday as investors celebrate a recent earnings report from GameStop (GME) with a surprise profit.
Via
InvestorPlace
Travelzoo, Semler Scientific, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
March 22, 2023
U.S. stocks traded mostly higher, with the Dow Jones gaining around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
SSYS Stock Alert: Stratasys Rejects Nano Dimension’s Takeover Offer
March 22, 2023
Stratasys (SSYS) stock is on the move Wednesday after the company rejected a $1.1 billion takeover offer from Nano Dimension.
Via
InvestorPlace
US Stocks Edge Lower Ahead Of Fed Decision; Nike Earnings Top Estimates
March 22, 2023
U.S. stocks traded slightly lower this morning. The Federal Reserve is scheduled to conclude a two-day policy meeting today, with markets expecting a 25 basis-point rate hike. Following the market...
Via
Benzinga
LAZR Stock Price Predictions: Why This Analyst Says Luminar Is Worth Just $5
March 22, 2023
Luminar (LAZR) stock is taking a beating on Wednesday as a new rating and price prediction weigh on the company's shares.
Via
InvestorPlace
Why Is 89bio (ETNB) Stock Up 34% Today?
March 22, 2023
89bio (ETNB) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial of pegozafermin.
Via
InvestorPlace
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
March 22, 2023
The battle pits 89bio and Akero in nonalcoholic steatohepatitis.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 22, 2023
Via
Benzinga
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
March 22, 2023
From
89bio, Inc.
Via
GlobeNewswire
Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday
March 20, 2023
HC Wainwright & Co. cut the price target for 89bio, Inc. (NASDAQ: ETNB) from $27 to $25. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. 89bio shares fell 5.2% to trade at $11.80 on...
Via
Benzinga
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 10, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
March 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday
February 21, 2023
Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in...
Via
Benzinga
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
February 21, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Provides Business Update and Outlook for 2023
January 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
20 Favorite Biotech & Medical Stocks For 2023
December 28, 2022
The way these stocks are setting up, many of them look great and will be at the forefront this coming year.
Via
Talk Markets
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
US Stocks Slightly Lower; Nasdaq Down 100 Points
December 19, 2022
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 100 points on Monday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 19, 2022
Via
Benzinga
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology
December 12, 2022
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
From
89bio, Inc.
Via
GlobeNewswire
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022
November 05, 2022
From
89bio, Inc.
Via
GlobeNewswire
ServiceNow, Teladoc Health And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
October 27, 2022
U.S. stock futures traded mostly higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.